Leading International Investment Research

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Leading International Investment Research, Edison Investment Research

Equity Bottom-Up

<p>With a positive primary endpoint plus 180-day data in acute graft versus host disease (aGvHD), Mesoblast is on track for its first US approval. Mesoblast is targeting US approval in H120 for GvHD and other key clinical trial endpoints, such as in Class II–III congestive heart failure (CHF) and lower back pain, and over the next two years is set to transition, assuming clinical and market success, into a profitable pharmaceutical company.</p>

With a positive primary endpoint plus 180-day data in acute graft versus host disease (aGvHD), Mesoblast is on track for its first US approval. Mesoblast is targeting US approval in H120 for GvHD and other key clinical trial endpoints, such as in Class II–III congestive heart failure (CHF) and lower back pain, and over the next two years is set to transition, assuming clinical and market success, into a profitable pharmaceutical company.

Mesoblast - Increasingly positive on aGvHD

Mesoblast Ltd

Mesoblast - Increasingly positive on aGvHD